ABSTRACT Introduction: P-glycoprotein (P-gp)/ABCB1 and breast cancer resistance protein
(BCRP)/ABCG2 are highly expressed in the placenta and fetus throughout gestation and …

Advances in genomic technologies have led to a wealth of information identifying genetic
polymorphisms in membrane transporters, specifically how these polymorphisms affect drug …

Determining the pathogenicity of genetic variants is a critical challenge, and functional
assessment is often the only option. Experimentally characterizing millions of possible …

Background Variability in genes implicated in drug pharmacokinetics or drug response can
modulate treatment efficacy or predispose to adverse drug reactions. Besides common …

Despite continuous research on chemotherapeutic agents, different mechanisms of
resistance have become a major pitfall in cancer chemotherapy. Although, exhaustive efforts …

Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment, in which
the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α …

ABSTRACT MDR1 is an ATP-dependent transmembrane transporter primarily studied for its
role in the detoxification of tissues and for its implication in resistance of tumor cells to …

Neutropenia is a common dose-limiting toxicity associated with irinotecan treatment.
Although UGT1A1 variants have been associated with neutropenia, a fraction of neutropenia …

Pentabromodiphenyl ethers (PBDE) are found in human tissue, in household dust, and in
the environment, and a particular concern is the potential for the induction of cancer …

The ability to block biological processes with selective small molecules provides advantages
distinct from most other experimental approaches. These include rapid time to onset, swift …